Brief: Ascentage Pharma Signs Option Agreement With Takeda To Enter Into Exclusive Global License For Olverembatinib
14/06/2024 14:40
June 14 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA SIGNS OPTION AGREEMENT WITH TAKEDA TO
ENTER
INTO EXCLUSIVE GLOBAL LICENSE FOR OLVEREMBATINIB, A
THIRD-GENERATION BCR-ABL TYROSINE KINASE INHIBITOR (TKI)
* CO TO RECEIVE ADDITIONAL POTENTIAL MILESTONES OF UP TO
APPROXIMATELY 1.2 BILLION USD, AND DOUBLE-DIGIT ROYALTIES ON
ANNUAL SALES
Source text for Eikon: ID:nPn55JJSza
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up